Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 18/20 | 0.66 |
| ▸ | ACE | P12821 | 4/20 | 0.64 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15202178 | 1.00 | MME (0.66) | MMEACEMMEL1 | |
| SCHEMBL15186431 | 0.93 | MME (0.57) | MMEACEMMEL1 | |
| SCHEMBL15472652 | 0.92 | MME (0.58) | MMEACEMMEL1 | |
| SCHEMBL19788069 | 0.92 | MME (0.58) | MMEACEMMEL1 | |
| SCHEMBL19687924 | 0.92 | MME (0.56) | MMEACE | |
| SCHEMBL15467742 | 0.92 | MME (0.56) | MMEACE | |
| SCHEMBL15467431 | 0.91 | MME (0.69) | MMEACEMMEL1 | |
| SCHEMBL15467397 | 0.91 | MME (0.63) | MMEACEMMEL1 | |
| SCHEMBL19687925 | 0.91 | MME (0.63) | MMEACEMMEL1 | |
| SCHEMBL19687841 | 0.91 | MME (0.58) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-11124502-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200283422-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-10570120-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190276442-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-09-12 | — | — | US | disclosed |
| US-10189823-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2882716-B9 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-8933111-B2 | Crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)-amino]-pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-8853427-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| EP-2675795-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Theravance, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130261316-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013123165-A1 | CRYSTALLINE FORM OF (2S,4R)-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-4-[(1H-[1,2,3]TRIAZOLE-4-CARBONYL)-AMINO]-PENTANOIC ACID [1,3]DIOXOL-4-YLMETHYL ESTER | THERAVANCE, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130209505-A1 | CRYSTALLINE FORM OF (2S,4R)-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-4-[(1H-[1,2,3]TRIAZOLE-4-CARBONYL)-AMINO]-PENTANOIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-08-15 | — | — | US | disclosed |
| US-8481044-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2012112742-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283422-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 212/4885 |
| US-20130209505-A1 | CRYSTALLINE FORM OF (2S,4R)-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-4-[(1H-[1,2,3]TRIAZOLE-4-CARBONYL)-AMINO]-PENTANOIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER | UACA, CYP4B1, FFAR4 | MME 1982/4885ACE 295/4885MMEL1 1532/4885 |
| US-20130261316-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 212/4885 |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
| US-11124502-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
| US-10189823-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
| US-20190276442-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
| US-10570120-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.